Hereditary Angioedema — Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Citation(s)
Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of rhC1INH for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2-13 Years of Age